NCT07102056

Brief Summary

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
152

participants targeted

Target at P50-P75 for all trials

Timeline
18mo left

Started Jan 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress23%
Jan 2026Dec 2027

First Submitted

Initial submission to the registry

July 8, 2025

Completed
26 days until next milestone

First Posted

Study publicly available on registry

August 3, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

January 1, 2026

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 3, 2027

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

December 29, 2025

Status Verified

December 1, 2024

Enrollment Period

1.4 years

First QC Date

July 8, 2025

Last Update Submit

December 25, 2025

Conditions

Neuroendocrine Tumors

Outcome Measures

Primary Outcomes (1)

  • Diagnostic efficacy

    Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms

    through study completion, an average of 1.5 year

Other Outcomes (1)

  • Prognostic Value of Baseline 18F-OC PET for Progression-Free Survival (PFS) in High-Risk Patients

    through study completion, 3-4 years

Interventions

18F-AlF-NOTA-Octreotide PET-CT or PET-MRDIAGNOSTIC_TEST

18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with a previous diagnosis of neuroendocrine tumors who are suspected of recurrence or metastasis.

You may qualify if:

  • Clinical diagnosed of neuroendocrine neoplasms.
  • Suspected of neuroendocrine neoplasms.

You may not qualify if:

  • Inability to undergo biopsy/surgical treatment.
  • Concurrent active malignancy.
  • Severe uncontrolled comorbidities/active infections.
  • Inability to provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve Tissue

Central Study Contacts

Donghe Chen

CONTACT

0571-87236432chendonghe@zju.edu.cn

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 8, 2025

First Posted

August 3, 2025

Study Start

January 1, 2026

Primary Completion (Estimated)

June 3, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

December 29, 2025

Record last verified: 2024-12